Bone in parathyroid diseases revisited: evidence from epidemiological, surgical and new drug outcomes.

Abstract

Parathyroid hormone (PTH)-related disorders have a major impact on bone metabolism and skeletal properties, due to the pivotal role of PTH in calcium and phosphate homeostasis and bone remodeling.Hyperparathyroidism is characterized by continuous exposure to excessive endogenous PTH, causing increased bone turnover in favor of bone resorption. Depending on the background of PTH overproduction, hyperparathyroidism is divided into primary, secondary and tertiary hyperparathyroidism.The clinical presentation varies from deterioration of bone microarchitecture and decreased bone mineral density (BMD) to profound bone involvement, such as osteitis fibrosa cystica and fragility fractures. Although successful parathyroidectomy represents the definitive treatment and may promote regression of most of the skeletal defects, the medical approach of calcimimetics and antiresorptive agents is a promising alternative in cases where parathyroidectomy is not feasible or unsuccessful.Hypoparathyroidism is the pathophysiological counterpart of hyperparathyroidism and also leads to disorders of bone metabolism and structure. Chronic PTH deprivation is associated with low bone remodeling and increased BMD. The defective microarchitecture might affect bone strength and raise the risk for adverse skeletal events. Recombinant human PTH acts as a replacement therapy and is safe and efficient in restoring calcium/phosphate homeostasis and bone turnover. However, it is approved only for refractory cases, as conventional management with calcium and active vitamin D remains the first-line treatment. This article reviews the skeletal involvement in the most frequent parathyroid disorders, hyperparathyroidism and hypoparathyroidism, along with rare familial disorders of PTH metabolism, as assessed by clinical, laboratory and imaging parameters, and the effect of the available treatment strategies.